UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and cabozantinib, can shrink tumors in people with head and neck cancer that has returned or spread and cannot be removed by surgery. The trial includes 36 adults with certain types of head and neck squamous cell carcino…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy aims to boost survival in hard-to-treat head and neck cancer
Disease control OngoingThis phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay tumor growth. About 252 adults whose cancer has spread or returned and cannot be removed b…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Double immune attack: new combo therapy targets Hard-to-Treat head and neck cancers
Disease control OngoingThis study tested a combination of two drugs—cetuximab and interleukin-12—in 23 people with head and neck cancer that had spread, returned, or could not be surgically removed. The goal was to find the safest dose of interleukin-12 when given with cetuximab and to see if the pair …
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:31 UTC